达芦那韦/柯比司他/恩曲他滨/替诺福韦艾拉酚胺治疗在意大利观察性队列中的有效性和安全性：DIAMANTE研究

IF 2.1 4区医学 Q3 VIROLOGY

Future Virology Pub Date : 2023-06-22 DOI:10.2217/fvl-2023-0065

A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, G. Rizzardini, M. Cossu, S. Rusconi, V. Esposito, A. Cascio, G. Orofino, M. Andreoni, E. Manzillo, A. Castagna, D. Mancusi, R. Termini, Marianna Portaro, A. Uglietti

{"title":"达芦那韦/柯比司他/恩曲他滨/替诺福韦艾拉酚胺治疗在意大利观察性队列中的有效性和安全性：DIAMANTE研究","authors":"A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, G. Rizzardini, M. Cossu, S. Rusconi, V. Esposito, A. Cascio, G. Orofino, M. Andreoni, E. Manzillo, A. Castagna, D. Mancusi, R. Termini, Marianna Portaro, A. Uglietti","doi":"10.2217/fvl-2023-0065","DOIUrl":null,"url":null,"abstract":"Aim: DIAMANTE is a retrospective and prospective, non-interventional, cohort study to describe the effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in real clinical practice in Italy. Patients & methods: The study enrolled 246 patients: group 1 included patients treated with a darunavir-based regimen (n = 81); group 2 included patients who received antiretroviral treatment not including darunavir before D/C/F/TAF (n = 43); and group 3 included naive patients (n = 122). Effectiveness was evaluated as the virological response at week 48. Results: The D/C/F/TAF virological response rate was 72.1–78.8% and was obtained despite longer follow-up intervals due to the coronavirus 2019 pandemic. The safety of D/C/F/TAF was good as was the overall patient satisfaction and quality of life. Conclusion: This study confirmed the effectiveness and tolerability of D/C/F/TAF in a real-life setting both in naive and pretreated patients, with and without darunavir. Clinical Trial Registration: NCT03577470 ( ClinicalTrials.gov )","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: the DIAMANTE study\",\"authors\":\"A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, G. Rizzardini, M. Cossu, S. Rusconi, V. Esposito, A. Cascio, G. Orofino, M. Andreoni, E. Manzillo, A. Castagna, D. Mancusi, R. Termini, Marianna Portaro, A. Uglietti\",\"doi\":\"10.2217/fvl-2023-0065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: DIAMANTE is a retrospective and prospective, non-interventional, cohort study to describe the effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in real clinical practice in Italy. Patients & methods: The study enrolled 246 patients: group 1 included patients treated with a darunavir-based regimen (n = 81); group 2 included patients who received antiretroviral treatment not including darunavir before D/C/F/TAF (n = 43); and group 3 included naive patients (n = 122). Effectiveness was evaluated as the virological response at week 48. Results: The D/C/F/TAF virological response rate was 72.1–78.8% and was obtained despite longer follow-up intervals due to the coronavirus 2019 pandemic. The safety of D/C/F/TAF was good as was the overall patient satisfaction and quality of life. Conclusion: This study confirmed the effectiveness and tolerability of D/C/F/TAF in a real-life setting both in naive and pretreated patients, with and without darunavir. Clinical Trial Registration: NCT03577470 ( ClinicalTrials.gov )\",\"PeriodicalId\":12505,\"journal\":{\"name\":\"Future Virology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-06-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/fvl-2023-0065\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Virology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fvl-2023-0065","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：DIAMANTE是一项回顾性、前瞻性、非介入性队列研究，旨在描述达芦那韦/柯比司他/恩曲他滨/替诺福韦艾拉酚胺（D/C/F/TAF）在意大利实际临床实践中的有效性。患者和方法：该研究纳入246名患者：第1组包括接受达鲁那韦方案治疗的患者（n=81）；第2组包括在D/C/F/TAF前接受不包括达芦那韦的抗逆转录病毒治疗的患者（n=43）；第3组包括幼稚患者（n=122）。有效性评估为第48周的病毒学反应。结果：D/C/F/TAF病毒学应答率为72.1–78.8%，尽管由于2019冠状病毒大流行，随访间隔更长，但仍获得了应答。D/C/F/TAF的安全性良好，患者的总体满意度和生活质量也良好。结论：本研究证实了D/C/F/TAF在现实生活中的有效性和耐受性，包括在未接受达芦那韦治疗和未接受治疗的患者中。临床试验注册：NCT03577470（ClinicalTrials.gov）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: the DIAMANTE study

Aim: DIAMANTE is a retrospective and prospective, non-interventional, cohort study to describe the effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in real clinical practice in Italy. Patients & methods: The study enrolled 246 patients: group 1 included patients treated with a darunavir-based regimen (n = 81); group 2 included patients who received antiretroviral treatment not including darunavir before D/C/F/TAF (n = 43); and group 3 included naive patients (n = 122). Effectiveness was evaluated as the virological response at week 48. Results: The D/C/F/TAF virological response rate was 72.1–78.8% and was obtained despite longer follow-up intervals due to the coronavirus 2019 pandemic. The safety of D/C/F/TAF was good as was the overall patient satisfaction and quality of life. Conclusion: This study confirmed the effectiveness and tolerability of D/C/F/TAF in a real-life setting both in naive and pretreated patients, with and without darunavir. Clinical Trial Registration: NCT03577470 ( ClinicalTrials.gov )

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Virology 医学-病毒学

CiteScore

4.00

自引率

3.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Future Virology is a peer-reviewed journal that delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this ever-expanding area of research. It is an interdisciplinary forum for all scientists working in the field today.